Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity.

Abstract

A replication-defective adenoviral vector, Ad.Egr-TNF.11D, was engineered by ligating the CArG (CC(A/T)6GG) elements of the Egr-1 gene promoter upstream to a cDNA encoding human tumor necrosis factor-alpha. We report here that Ad.Egr-TNF.11D is activated by the clinically important anticancer agents cisplatin, cyclophosphamide, doxorubicin, 5-fluorouracil… (More)

Topics

5 Figures and Tables

Cite this paper

@article{Lpez2004ChemoinducibleGT, title={Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity.}, author={Carlos Alberola L{\'o}pez and Eric T. Kimchi and Helena J. Mauceri and James Park and Neil Mehta and Kevin T. Murphy and Michael A. Beckett and Samuel Hellman and Mitchell C. Posner and Donald Kufe and Ralph R. Weichselbaum}, journal={Molecular cancer therapeutics}, year={2004}, volume={3 9}, pages={1167-75} }